De novo cancer in transplant recipients.
Kim
M S
MS
Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Kim
S I
SI
Kim
Y S
YS
Oh
C K
CK
Park
K
K
D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D016009:Chi-Square Distribution; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005770:Gastrointestinal Neoplasms / Q000453:epidemiology; D006084:Graft Rejection / Q000453:epidemiology / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D016030:Kidney Transplantation; D008175:Lung Neoplasms / Q000453:epidemiology; D008223:Lymphoma / Q000453:epidemiology; D016853:Muromonab-CD3 / Q000627:therapeutic use; D009369:Neoplasms / Q000453:epidemiology* / Q000628:therapy; D011183:Postoperative Complications; D012189:Retrospective Studies; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3